SEC Form 4 · Rule 10b5-1 trading plans

BridgeBio Pharma, Inc. (BBIO)

45Trades filed under a plan
5Plan adoption dates stated
9Quarterly results prints on file
4Trades in the days before a print

In the 2025 filing year, BridgeBio Pharma, Inc. filed 15 Form 4 statements whose footnotes name a Rule 10b5-1 trading plan, by 6 reporting owners, covering 45 transactions filed under those plans and 1,475,742 shares. 14 of those filings carry the SEC's own AFF10B5ONE adoption flag; the other 1 name a plan in a footnote and carry no flag. 9 results prints are on file in the same window, which is what makes the interval below measurable.

Trades filed under a plan in BridgeBio Pharma, Inc. 45

Plan adoption dates stated in BridgeBio Pharma, Inc. 5

Quarterly results prints on file in BridgeBio Pharma, Inc. 9

Trades in the days before a print in BridgeBio Pharma, Inc. 4

Interval to the next reported results date

For each transaction filed under a plan, the days between the transaction date and the company’s next results print. These are the dates the filings state, printed as an interval; the page draws no conclusion from them.

4Within 5 days of a print
4Within 10 days of a print
0Shortest interval, in days
0Trades with no later print on file

Adoption dates, as the filings state them

As the filings state it: “10b5-1 sales plan adopted by the Reporting Person on March 22, 2024”

Reported results dates on file

A proxy statement is on file for this company in the same window, which is where a company states its own trading policy.

Other companies with plan records

Order the document

Every company with plan records →

Form 4 statements and their footnotes from the SEC’s EDGAR full-text search, and this company’s results dates, industry classification and state of incorporation from the SEC submissions API. The page prints the dates the filings state and the interval between them; it draws no conclusion from them.